This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Ravulizumab in myasthenia gravis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ) (1)

  • approximately 80-90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR)
    • a major drive of AChR antibody-positive MG pathology is represented by complement activation
    • role of the complement cascade has been largely demonstrated in patients and in MG animal models
    • complement activation at the NMJ leads to focal lysis of the post-synaptic membrane, disruption of the characteristic folds, and reduction of AChRs
      • binding of anti-AChR antibodies leads to activation of the classical complement cascade, formation of the terminal complement complex (membrane attack complex), and consequent destruction of the postsynaptic membrane of the neuromuscular junction

  • Ravulizumab
    • is a humanized monoclonal antibody that specifically binds with high affinity to the human terminal complement protein C5, preventing disruption of neuromuscular transmission, presumably by inhibiting membrane attack complex-mediated destruction of the neuromuscular junction
    • has demonstrated rapid and sustained improvements in both patient- and clinician-reported outcomes and had a side effect and adverse-event profile that did not limit treatment in adults with anti-AChR antibody-positive gMG (2)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.